Escient Pharmaceuticals Announces Presentation of Data Demonstrating Efficacy of EP262 in Inhibition of Mast Cell Degranulation in Multiple Species at the European Academy of Allergy and Clinical Immunology
Data shows that EP262 attenuates mast cell degranulation in multiple species including human MRGPRX2 knock-in mice, Beagle dogs and human ex vivo skin explants Results support the initiation
San Diego United States Mecklenburg Vorpommern Stefan Klotter Aaron Mishel Escient Pharmaceuticals Inc
Source: finanznachrichten.de